Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

Abstract

The aggregate study results, from the parent and open-label extension suggest that future testing with GDNF will likely require an 80- rather than a 40-week randomized treatment period and/or a higher dose.